CO2022008684A2 - Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3 - Google Patents

Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3

Info

Publication number
CO2022008684A2
CO2022008684A2 CONC2022/0008684A CO2022008684A CO2022008684A2 CO 2022008684 A2 CO2022008684 A2 CO 2022008684A2 CO 2022008684 A CO2022008684 A CO 2022008684A CO 2022008684 A2 CO2022008684 A2 CO 2022008684A2
Authority
CO
Colombia
Prior art keywords
antibodies
formulations containing
human
stabilized formulations
containing bispecific
Prior art date
Application number
CONC2022/0008684A
Other languages
English (en)
Spanish (es)
Inventor
Yuan Cheng
Xiaolin Tang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74141846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2022008684(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2022008684A2 publication Critical patent/CO2022008684A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CONC2022/0008684A 2019-12-10 2022-06-22 Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3 CO2022008684A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962946207P 2019-12-10 2019-12-10
PCT/US2020/064025 WO2021119135A1 (en) 2019-12-10 2020-12-09 Stabilized formulations containing anti-cd20 x anti-cd3 bispecific antibodies

Publications (1)

Publication Number Publication Date
CO2022008684A2 true CO2022008684A2 (es) 2022-06-30

Family

ID=74141846

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008684A CO2022008684A2 (es) 2019-12-10 2022-06-22 Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3

Country Status (15)

Country Link
US (2) US20210206870A1 (enExample)
EP (1) EP4072585A1 (enExample)
JP (2) JP7813703B2 (enExample)
KR (1) KR20220113417A (enExample)
CN (1) CN115003331A (enExample)
AU (1) AU2020402030A1 (enExample)
BR (1) BR112022011150A2 (enExample)
CA (1) CA3161059A1 (enExample)
CL (3) CL2022001495A1 (enExample)
CO (1) CO2022008684A2 (enExample)
IL (1) IL293372A (enExample)
MY (1) MY210570A (enExample)
PH (1) PH12022551275A1 (enExample)
TW (1) TW202135860A (enExample)
WO (1) WO2021119135A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202400228A (zh) 2022-02-25 2024-01-01 美商再生元醫藥公司 減輕細胞激素釋放症候群的給藥方案

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
ES2537738T3 (es) * 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
JP2012041317A (ja) * 2010-08-23 2012-03-01 Panasonic Corp フェロセン修飾抗体
WO2012135408A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HUE050159T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
ES2809455T3 (es) * 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
CN108602889A (zh) * 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
TWI865430B (zh) * 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法
MA49960A (fr) * 2017-08-25 2021-06-02 Omeros Corp Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique
CA3202891A1 (en) * 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome

Also Published As

Publication number Publication date
CA3161059A1 (en) 2021-06-17
MY210570A (en) 2025-09-30
WO2021119135A1 (en) 2021-06-17
US20210206870A1 (en) 2021-07-08
CN115003331A (zh) 2022-09-02
TW202135860A (zh) 2021-10-01
EP4072585A1 (en) 2022-10-19
JP2026016480A (ja) 2026-02-03
IL293372A (en) 2022-07-01
JP7813703B2 (ja) 2026-02-13
US20250236677A1 (en) 2025-07-24
KR20220113417A (ko) 2022-08-12
BR112022011150A2 (pt) 2022-08-23
PH12022551275A1 (en) 2024-01-08
JP2023507561A (ja) 2023-02-24
AU2020402030A1 (en) 2022-07-28
CL2022001495A1 (es) 2023-01-13
CL2024001536A1 (es) 2024-10-18
CL2024003444A1 (es) 2025-04-11

Similar Documents

Publication Publication Date Title
CO2019011021A2 (es) Formulacion estable de anticuerpos
ECSP12012092A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2025010757A (es) Formulacion farmaceutica de ph bajo
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
MX2019008084A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
UY33515A (es) Formulaciones estabilizadas que contienen anticuerpos anti-ngf
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CL2021002440A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33.
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
CL2022001495A1 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3.
CO2023014918A2 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3
UY33652A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
CO2026000834A2 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-bcma x anti-cd3
JOP20240028A1 (ar) جسيمات شحمية تتضمن ببتيدات تاو الفسفورية لتحفيز الاستجابات المناعية المستدامة
CY1125584T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
CO2022009693A2 (es) Formulación estable y de alta concentración del anticuerpo nimotuzumab
TN2012000342A1 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies